ATAD2 as a Cancer Target: Insights into Its Structure, Functions, Mechanisms, and Drug Development
Cancers · 16.10.2025 · 17 (20) · 3337
DOI: 10.3390/cancers17203337 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 16.10.2025. Verfasst von Tanya Garain und 3 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Biosciences, Middle Tennessee State University, Murfreesboro, TN 37130, USA. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 135 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NIH HHS, NCI NIH HHS.
Abstract (Originalsprache)
ATPase family AAA domain-containing protein 2 (ATAD2) has been recognized as a key oncogene that regulates chromatin remodeling, transcription, and cancer progression. As a member of the bromodomain (BRD) family, ATAD2 plays a crucial role in epigenetic modifications and is associated with multiple malignancies. Despite being considered an undruggable target in the past, crystallography and computational modeling have significantly accelerated ATAD2 drug discovery and development. This review provides a comprehensive overview of the structural features, functional roles, and biological significance of ATAD2, particularly in the context of cancer. We present an in-depth overview of different molecular strategies reported in the literature to suppress ATAD2 expression, including genetic and pharmacological approaches, and discuss their mechanistic and therapeutic implications. Particular emphasis is given to recent efforts in developing small-molecule inhibitors, detailing their binding interactions, therapeutic potential, and challenges in clinical translation. In addition, we performed alanine scanning calculations on molecular dynamics (MD)-simulated trajectories derived from protein–ligand complexes based on X-ray co-crystal structures containing three distinct ligands with different binding modes. This analysis provided critical insights into the binding interface of BRD-ATAD2, enhancing our understanding of its ligand interactions. Furthermore, we examine the emerging roles of ATAD2 in mediating resistance to cancer therapies, underscoring its potential as a target for overcoming drug resistance. By integrating structural insights, mechanistic studies, drug discovery efforts, and the challenges of developing ATAD2-targeted cancer therapies, this review emphasizes the need for further research to optimize ATAD2 inhibition strategies and explore its full therapeutic potential in oncology.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Molecular Biosciences, Middle Tennessee State University, Murfreesboro, TN 37130, USA.
- Department of Chemistry, Middle Tennessee State University, Murfreesboro, TN 37130, USA.
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
ORCID-Profile: Tanya Garain, Prateek Rai, Wei Li, Souvik Banerjee
Förderung
- NIGMS NIH HHS
- NIH HHS
- NCI NIH HHS
- NIH
Zitieren
APA
Garain, T., Rai, P., Li, W., & Banerjee, S. (2025). ATAD2 as a Cancer Target: Insights into Its Structure, Functions, Mechanisms, and Drug Development. Cancers, 17(20), 3337. https://doi.org/10.3390/cancers17203337
Vancouver
Garain T, Rai P, Li W, Banerjee S. ATAD2 as a Cancer Target: Insights into Its Structure, Functions, Mechanisms, and Drug Development. Cancers. 2025;17(20):3337. doi:10.3390/cancers17203337
BibTeX
@article{Garain2025,
author = {Garain, Tanya and Rai, Prateek and Li, Wei and Banerjee, Souvik},
title = {ATAD2 as a Cancer Target: Insights into Its Structure, Functions, Mechanisms, and Drug Development},
journal = {Cancers},
year = {2025},
volume = {17},
number = {20},
pages = {3337},
doi = {10.3390/cancers17203337}
}
EUVIMED